Full Breakdown
UC Berkeley Researchers Reveal Metabolic Compound That Boosts Energy Use and Enhances GLP-1 Therapy in Mice
8/23/2026, 7:54:30 PM
A New Metabolic Approach Targets Energy Expenditure
Researchers at the University of California, Berkeley reported on August 21 in *Science Advances* that the small-molecule 5-tetradecyloxy-2-furoic acid (TOFA) simultaneously blocks lipid synthesis and activates cellular receptors PPAR? and PPAR?. The dual action raised whole-body energy expenditure by as much as 18 % in obese mice without increasing physical activity or body temperature.
Context: GLP-1 Drugs and Their Limitations
GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) achieve weight loss primarily by suppressing appetite. While effective, they can cause gastrointestinal side effects and may lead to nutritional deficiencies, loss of muscle mass, and frailty over time. The Berkeley team therefore pursued a strategy that augments the second lever of body-weight regulation—energy expenditure.
Study Design and Key Findings in Mice
In a series of mouse experiments, TOFA improved insulin sensitivity, lowered blood glucose, and reduced circulating triglycerides and hepatic fat. Treated animals lost adipose tissue while preserving lean muscle mass. When combined with GLP-1 drugs, TOFA produced additive improvements in body weight, glucose control, insulin levels, and triglyceride reduction compared with either approach alone. Anders Näär, professor of metabolic biology and nutrition and senior author, described the compound as “complementary rather than a replacement” for appetite-suppressing therapies. First author Justin Y. Lee, a postdoctoral researcher at UCSF, noted that TOFA “engages a coordinated metabolic response” that helps the body handle excess lipids and glucose more effectively.
Potential Clinical Impact and Next Steps
The findings suggest that a single agent capable of both limiting lipid production and enhancing fat oxidation could broaden treatment options for obesity, type 2 diabetes, and fatty-liver disease. However, the research has so far been limited to animal models; safety and efficacy in humans remain untested. To advance toward clinical use, the investigators have formed ReRx Therapeutics with support from Berkeley’s life-sciences entrepreneurship ecosystem. Future work will focus on pre-clinical safety assessments and, ultimately, human trials.
